Editorial Policy & Evidence Standards (E-E-A-T)

Published by the OncoGuides Clinical Governance Board

1. Commitment to Evidence-Based Neuro-Oncology

NeuroOncoGuides produces content grounded strictly in peer-reviewed clinical neurology and oncology research, international consensus guidelines, and randomized controlled trial data. Our clinical synthesis reflects authoritative guidance from:

American Society of Clinical Oncology (ASCO) — CIPN Prevention and Management Guidelines
Multinational Association of Supportive Care in Cancer (MASCC) / ESMO — Neurological Toxicity Guidelines
American Society for Radiation Oncology (ASTRO) & Society for Neuro-Oncology (SNO)
American Society for Transplantation and Cellular Therapy (ASTCT) — ICANS Consensus Criteria

2. Clinical Evidence Hierarchy

We classify all recommendations using standard international evidence hierarchies:

Level A: Supported by multiple randomized controlled clinical trials or meta-analyses (e.g., CALGB 170601 for Duloxetine in CIPN).
Level B: Supported by single randomized trials or large prospective registry cohorts (e.g. Compounded BAK Gel, Bevacizumab for Radionecrosis).
Level C: Supported by expert consensus, mechanistic pharmacology, and institutional supportive care protocols.

3. Commercial Independence & Non-Bias

NeuroOncoGuides maintains complete editorial independence. We do not accept pharmaceutical sponsorship, paid product placements, or commercial endorsements. All neuropathy drugs and assistive devices are evaluated purely on scientific efficacy and safety merits.